{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T07:16:05Z","timestamp":1760080565960},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T00:00:00Z","timestamp":1632700800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T00:00:00Z","timestamp":1632700800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1007\/s11899-021-00650-4","type":"journal-article","created":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T18:08:12Z","timestamp":1632766092000},"page":"464-472","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Avapritinib in the Treatment of Systemic Mastocytosis: an Update"],"prefix":"10.1007","volume":"16","author":[{"given":"Samantha","family":"Below","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura C.","family":"Michaelis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,9,27]]},"reference":[{"issue":"20","key":"650_CR1","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391\u2013405.","journal-title":"Blood"},{"issue":"18","key":"650_CR2","doi-asserted-by":"publisher","first-page":"3769","DOI":"10.1182\/blood-2009-05-220145","volume":"114","author":"A Pardanani","year":"2009","unstructured":"Pardanani A, Lim KH, Lasho TL, Finke C, McClure RF, Li CY, et al. Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies. Blood. 2009;114(18):3769\u201372.","journal-title":"Blood"},{"issue":"23","key":"650_CR3","doi-asserted-by":"publisher","first-page":"10560","DOI":"10.1073\/pnas.92.23.10560","volume":"92","author":"H Nagata","year":"1995","unstructured":"Nagata H, Worobec AS, Oh CK, Chowdhury BA, Tannenbaum S, Suzuki Y, et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci U S A. 1995;92(23):10560\u20134.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"16","key":"650_CR4","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1182\/blood.2019000932","volume":"135","author":"A Reiter","year":"2020","unstructured":"Reiter A, George TI, Gotlib J. New developments in diagnosis, prognostication, and treatment of advanced systemic mastocytosis. Blood. 2020;135(16):1365\u201376.","journal-title":"Blood"},{"issue":"6","key":"650_CR5","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1038\/leu.2015.24","volume":"29","author":"M Arock","year":"2015","unstructured":"Arock M, Sotlar K, Akin C, Broesby-Olsen S, Hoermann G, Escribano L, et al. KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis. Leukemia. 2015;29(6):1223\u201332.","journal-title":"Leukemia"},{"issue":"23","key":"650_CR6","doi-asserted-by":"publisher","first-page":"5727","DOI":"10.1182\/blood-2009-02-205237","volume":"113","author":"KH Lim","year":"2009","unstructured":"Lim KH, Tefferi A, Lasho TL, Finke C, Patnaik M, Butterfield JH, et al. Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood. 2009;113(23):5727\u201336.","journal-title":"Blood"},{"issue":"7","key":"650_CR7","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.1182\/blood-2006-04-015545","volume":"108","author":"AC Garcia-Montero","year":"2006","unstructured":"Garcia-Montero AC, Jara-Acevedo M, Teodosio C, Sanchez ML, Nunez R, Prados A, et al. KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood. 2006;108(7):2366\u201372.","journal-title":"Blood"},{"issue":"16","key":"650_CR8","doi-asserted-by":"publisher","first-page":"3085","DOI":"10.1182\/blood-2013-01-453183","volume":"121","author":"A Pardanani","year":"2013","unstructured":"Pardanani A. How I treat patients with indolent and smoldering mastocytosis (rare conditions but difficult to manage). Blood. 2013;121(16):3085\u201394.","journal-title":"Blood"},{"issue":"4","key":"650_CR9","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.ijwd.2020.05.013","volume":"6","author":"L Kibsgaard","year":"2020","unstructured":"Kibsgaard L, Deleuran M, Flohr C, Langan S, BraaeOlesen A, Vestergaard C. How, \u201cbenign\u201d is cutaneous mastocytosis? A Danish registry-based matched cohort study. Int J Womens Dermatol. 2020;6(4):294\u2013300.","journal-title":"Int J Womens Dermatol"},{"issue":"1","key":"650_CR10","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1002\/ajh.25302","volume":"94","author":"A Tefferi","year":"2019","unstructured":"Tefferi A, Shah S, Reichard KK, Hanson CA, Pardanani A. Smoldering mastocytosis: survival comparisons with indolent and aggressive mastocytosis. Am J Hematol. 2019;94(1):E1\u20132.","journal-title":"Am J Hematol"},{"issue":"5","key":"650_CR11","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1038\/s41375-019-0450-8","volume":"33","author":"J Lubke","year":"2019","unstructured":"Lubke J, Naumann N, Kluger S, Schwaab J, Metzgeroth G, Evans E, et al. Inhibitory effects of midostaurin and avapritinib on myeloid progenitors derived from patients with KIT D816V positive advanced systemic mastocytosis. Leukemia. 2019;33(5):1195\u2013205.","journal-title":"Leukemia"},{"issue":"26","key":"650_CR12","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1056\/NEJMoa1513098","volume":"374","author":"J Gotlib","year":"2016","unstructured":"\u2022\u2022 Gotlib J, Kluin-Nelemans HC, George TI, Akin C, Sotlar K, Hermine O, et al. Efficacy and safety of midostaurin in advanced systemic mastocytosis. N Engl J Med. 2016;374(26):2530\u201341. Practice-changing data of first targeted agent in rare disease.","journal-title":"N Engl J Med"},{"issue":"2","key":"650_CR13","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1038\/leu.2017.234","volume":"32","author":"DJ DeAngelo","year":"2018","unstructured":"\u2022 DeAngelo DJ, George TI, Linder A, Langford C, Perkins C, Ma J, et al. Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial. Leukemia. 2018;32(2):470\u20138. An important follow up of key phase II trial of midostaurin in patients with aggressive systemic mastocytosis.","journal-title":"Leukemia"},{"issue":"3","key":"650_CR14","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/ajh.25371","volume":"94","author":"A Pardanani","year":"2019","unstructured":"Pardanani A. Systemic mastocytosis in adults: 2019 update on diagnosis, risk stratification and management. Am J Hematol. 2019;94(3):363\u201377.","journal-title":"Am J Hematol"},{"issue":"12","key":"650_CR15","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.6004\/jnccn.2018.0088","volume":"16","author":"J Gotlib","year":"2018","unstructured":"Gotlib J, Gerds AT, Bose P, Castells MC, Deininger MW, Gojo I, et al. Systemic mastocytosis, version 2.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2018;16(12):1500\u201337.","journal-title":"J Natl Compr Canc Netw"},{"issue":"4","key":"650_CR16","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1002\/ajh.26118","volume":"96","author":"A Pardanani","year":"2021","unstructured":"Pardanani A. Systemic mastocytosis in adults: 2021 update on diagnosis, risk stratification and management. Am J Hematol. 2021;96(4):508\u201325.","journal-title":"Am J Hematol"},{"issue":"1","key":"650_CR17","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1182\/asheducation-2018.1.127","volume":"2018","author":"W Shomali","year":"2018","unstructured":"Shomali W, Gotlib J. The new tool \u201cKIT\u201d in advanced systemic mastocytosis. Hematology Am Soc Hematol Educ Program. 2018;2018(1):127\u201336.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"1","key":"650_CR18","doi-asserted-by":"publisher","first-page":"292","DOI":"10.7150\/thno.51872","volume":"11","author":"HC Kluin-Nelemans","year":"2021","unstructured":"Kluin-Nelemans HC, Jawhar M, Reiter A, van Anrooij B, Gotlib J, Hartmann K, et al. Cytogenetic and molecular aberrations and worse outcome for male patients in systemic mastocytosis. Theranostics. 2021;11(1):292\u2013303.","journal-title":"Theranostics"},{"key":"650_CR19","doi-asserted-by":"publisher","unstructured":"Gotlib J, Kluin-Nelemans HC, Akin C, Hartmann K, Valent P, Reiter A. Practical management of adverse events in patients with advanced systemic mastocytosis receiving midostaurin. Expert Opin Biol Ther. 2021;21(4):487-498. https:\/\/doi.org\/10.1080\/14712598.2021.1837109. Epub 2021 Jan 15. PMID: 33063554.","DOI":"10.1080\/14712598.2021.1837109"},{"issue":"3","key":"650_CR20","doi-asserted-by":"publisher","first-page":"e194","DOI":"10.1016\/S2352-3026(20)30400-2","volume":"8","author":"JI Munoz-Gonzalez","year":"2021","unstructured":"Munoz-Gonzalez JI, Alvarez-Twose I, Jara-Acevedo M, Zanotti R, Perkins C, Jawhar M, et al. Proposed global prognostic score for systemic mastocytosis: a retrospective prognostic modelling study. Lancet Haematol. 2021;8(3):e194\u2013204.","journal-title":"Lancet Haematol"},{"issue":"2","key":"650_CR21","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1097\/MOH.0000000000000486","volume":"26","author":"L Fletcher","year":"2019","unstructured":"Fletcher L, Borate U. Novel approaches for systemic mastocytosis. Curr Opin Hematol. 2019;26(2):112\u20138.","journal-title":"Curr Opin Hematol"},{"issue":"1","key":"650_CR22","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/bjh.14967","volume":"180","author":"RM Scherber","year":"2018","unstructured":"Scherber RM, Borate U. How we diagnose and treat systemic mastocytosis in adults. Br J Haematol. 2018;180(1):11\u201323.","journal-title":"Br J Haematol"},{"issue":"6","key":"650_CR23","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1158\/0008-5472.CAN-16-2234","volume":"77","author":"P Valent","year":"2017","unstructured":"Valent P, Akin C, Hartmann K, Nilsson G, Reiter A, Hermine O, et al. Advances in the classification and treatment of mastocytosis: current status and outlook toward the future. Cancer Res. 2017;77(6):1261\u201370.","journal-title":"Cancer Res"},{"key":"650_CR24","first-page":"77","volume":"11","author":"JA Gilreath","year":"2019","unstructured":"Gilreath JA, Tchertanov L, Deininger MW. Novel approaches to treating advanced systemic mastocytosis. Clin Pharmacol. 2019;11:77\u201392.","journal-title":"Clin Pharmacol"},{"issue":"11","key":"650_CR25","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1056\/NEJMoa022457","volume":"348","author":"SG O\u2019Brien","year":"2003","unstructured":"O\u2019Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348(11):994\u20131004.","journal-title":"N Engl J Med"},{"issue":"9","key":"650_CR26","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1056\/NEJM199202273260907","volume":"326","author":"HC Kluin-Nelemans","year":"1992","unstructured":"Kluin-Nelemans HC, Jansen JH, Breukelman H, Wolthers BG, Kluin PM, Kroon HM, et al. Response to interferon alfa-2b in a patient with systemic mastocytosis. N Engl J Med. 1992;326(9):619\u201323.","journal-title":"N Engl J Med"},{"issue":"4","key":"650_CR27","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1159\/000204898","volume":"85","author":"S Pardini","year":"1991","unstructured":"Pardini S, Bosincu L, Bonfigli S, Dore F, Longinotti M. Anaphylactic-like syndrome in systemic mastocytosis treated with alpha-2-interferon. Acta Haematol. 1991;85(4):220.","journal-title":"Acta Haematol"},{"issue":"10","key":"650_CR28","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s002770050604","volume":"78","author":"T Lehmann","year":"1999","unstructured":"Lehmann T, Lammle B. IFNalpha treatment in systemic mastocytosis. Ann Hematol. 1999;78(10):483\u20134.","journal-title":"Ann Hematol"},{"key":"650_CR29","doi-asserted-by":"publisher","unstructured":"Arun VA, Soni D, Bal A, Jain A. Aggressive systemic mastocytosis presenting as rapidly progressive ascites, generalised lymphadenopathy and osteosclerosis. BMJ Case Rep. 2021;14(2):e238034. https:\/\/doi.org\/10.1136\/bcr-2020-238034. PMID: 33558379; PMCID: PMC7872913.","DOI":"10.1136\/bcr-2020-238034"},{"issue":"4","key":"650_CR30","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1046\/j.1365-2141.2002.03944.x","volume":"119","author":"P Casassus","year":"2002","unstructured":"Casassus P, Caillat-Vigneron N, Martin A, Simon J, Gallais V, Beaudry P, et al. Treatment of adult systemic mastocytosis with interferon-alpha: results of a multicentre phase II trial on 20 patients. Br J Haematol. 2002;119(4):1090\u20137.","journal-title":"Br J Haematol"},{"issue":"4","key":"650_CR31","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1056\/NEJM200101253440415","volume":"344","author":"A Tefferi","year":"2001","unstructured":"Tefferi A, Li CY, Butterfield JH, Hoagland HC. Treatment of systemic mast-cell disease with cladribine. N Engl J Med. 2001;344(4):307\u20139.","journal-title":"N Engl J Med"},{"issue":"13","key":"650_CR32","doi-asserted-by":"publisher","first-page":"4270","DOI":"10.1182\/blood-2003-05-1699","volume":"102","author":"HC Kluin-Nelemans","year":"2003","unstructured":"Kluin-Nelemans HC, Oldhoff JM, Van Doormaal JJ, Van\u2019tWout JW, Verhoef G, Gerrits WB, et al. Cladribine therapy for systemic mastocytosis. Blood. 2003;102(13):4270\u20136.","journal-title":"Blood"},{"issue":"12","key":"650_CR33","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1002\/ajh.21561","volume":"84","author":"KH Lim","year":"2009","unstructured":"Lim KH, Pardanani A, Butterfield JH, Li CY, Tefferi A. Cytoreductive therapy in 108 adults with systemic mastocytosis: outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine. Am J Hematol. 2009;84(12):790\u20134.","journal-title":"Am J Hematol"},{"issue":"8","key":"650_CR34","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1182\/blood-2014-12-614743","volume":"126","author":"S Barete","year":"2015","unstructured":"Barete S, Lortholary O, Damaj G, Hirsch I, Chandesris MO, Elie C, et al. Long-term efficacy and safety of cladribine (2-CdA) in adult patients with mastocytosis. Blood. 2015;126(8):1009\u201316 (quiz 50).","journal-title":"Blood"},{"key":"650_CR35","doi-asserted-by":"publisher","first-page":"443","DOI":"10.3389\/fphar.2020.00443","volume":"11","author":"M Piris-Villaespesa","year":"2020","unstructured":"Piris-Villaespesa M, Alvarez-Twose I. Systemic mastocytosis: following the tyrosine kinase inhibition roadmap. Front Pharmacol. 2020;11:443.","journal-title":"Front Pharmacol"},{"issue":"11","key":"650_CR36","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1007\/s00432-015-1988-0","volume":"141","author":"A Hochhaus","year":"2015","unstructured":"Hochhaus A, Baccarani M, Giles FJ, le Coutre PD, Muller MC, Reiter A, et al. Nilotinib in patients with systemic mastocytosis: analysis of the phase 2, open-label, single-arm nilotinib registration study. J Cancer Res Clin Oncol. 2015;141(11):2047\u201360.","journal-title":"J Cancer Res Clin Oncol"},{"key":"650_CR37","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.phrs.2018.04.020","volume":"133","author":"R Roskoski Jr","year":"2018","unstructured":"Roskoski R Jr. The role of small molecule Kit protein-tyrosine kinase inhibitors in the treatment of neoplastic disorders. Pharmacol Res. 2018;133:35\u201352.","journal-title":"Pharmacol Res"},{"key":"650_CR38","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.12688\/f1000research.13343.1","volume":"6","author":"GJ Molderings","year":"2017","unstructured":"Molderings GJ, Afrin LB, Hertfelder HJ, Brettner S. Case report: treatment of systemic mastocytosis with sunitinib. F1000Res. 2017;6:2182.","journal-title":"F1000Res"},{"issue":"6","key":"650_CR39","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1111\/ejh.12606","volume":"95","author":"LB Afrin","year":"2015","unstructured":"Afrin LB, Cichocki FM, Patel K, Molderings GJ. Successful treatment of mast cell activation syndrome with sunitinib. Eur J Haematol. 2015;95(6):595\u20137.","journal-title":"Eur J Haematol"},{"issue":"4","key":"650_CR40","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1111\/bjh.16092","volume":"187","author":"E Weisberg","year":"2019","unstructured":"Weisberg E, Meng C, Case AE, Sattler M, Tiv HL, Gokhale PC, et al. Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies. Br J Haematol. 2019;187(4):488\u2013501.","journal-title":"Br J Haematol"},{"issue":"47","key":"650_CR41","doi-asserted-by":"publisher","first-page":"82897","DOI":"10.18632\/oncotarget.19970","volume":"8","author":"KM Kampa-Schittenhelm","year":"2017","unstructured":"Kampa-Schittenhelm KM, Frey J, Haeusser LA, Illing B, Pavlovsky AA, Blumenstock G, et al. Crenolanib is a type I tyrosine kinase inhibitor that inhibits mutant KIT D816 isoforms prevalent in systemic mastocytosis and core binding factor leukemia. Oncotarget. 2017;8(47):82897\u2013909.","journal-title":"Oncotarget"},{"issue":"7","key":"650_CR42","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1182\/blood-2010-06-289959","volume":"118","author":"KV Gleixner","year":"2011","unstructured":"Gleixner KV, Mayerhofer M, Cerny-Reiterer S, Hormann G, Rix U, Bennett KL, et al. KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib. Blood. 2011;118(7):1885\u201398.","journal-title":"Blood"},{"issue":"1","key":"650_CR43","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1182\/blood-2005-10-3969","volume":"108","author":"NP Shah","year":"2006","unstructured":"Shah NP, Lee FY, Luo R, Jiang Y, Donker M, Akin C. Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis. Blood. 2006;108(1):286\u201391.","journal-title":"Blood"},{"issue":"1","key":"650_CR44","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/j.1600-0609.2012.01761.x","volume":"89","author":"S Georgin-Lavialle","year":"2012","unstructured":"Georgin-Lavialle S, Lhermitte L, Suarez F, Yang Y, Letard S, Hanssens K, et al. Mast cell leukemia: identification of a new c-Kit mutation, dup(501\u2013502), and response to masitinib, a c-Kit tyrosine kinase inhibitor. Eur J Haematol. 2012;89(1):47\u201352.","journal-title":"Eur J Haematol"},{"key":"650_CR45","doi-asserted-by":"publisher","first-page":"105463","DOI":"10.1016\/j.phrs.2021.105463","volume":"165","author":"R Roskoski Jr","year":"2021","unstructured":"Roskoski R Jr. Properties of FDA-approved small molecule protein kinase inhibitors: a 2021 update. Pharmacol Res. 2021;165:105463.","journal-title":"Pharmacol Res"},{"issue":"9383","key":"650_CR46","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/S0140-6736(03)14115-3","volume":"362","author":"A Pardanani","year":"2003","unstructured":"Pardanani A, Elliott M, Reeder T, Li CY, Baxter EJ, Cross NC, et al. Imatinib for systemic mast-cell disease. Lancet. 2003;362(9383):535\u20136.","journal-title":"Lancet"},{"issue":"5","key":"650_CR47","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1182\/blood.V99.5.1741","volume":"99","author":"Y Ma","year":"2002","unstructured":"Ma Y, Zeng S, Metcalfe DD, Akin C, Dimitrijevic S, Butterfield JH, et al. The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood. 2002;99(5):1741\u20134.","journal-title":"Blood"},{"issue":"5","key":"650_CR48","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1038\/sj.onc.1206120","volume":"22","author":"Y Zermati","year":"2003","unstructured":"Zermati Y, De Sepulveda P, Feger F, Letard S, Kersual J, Casteran N, et al. Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms. Oncogene. 2003;22(5):660\u20134.","journal-title":"Oncogene"},{"issue":"2","key":"650_CR49","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1002\/cncr.21996","volume":"107","author":"HJ Droogendijk","year":"2006","unstructured":"Droogendijk HJ, Kluin-Nelemans HJ, van Doormaal JJ, Oranje AP, van de Loosdrecht AA, van Daele PL. Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial. Cancer. 2006;107(2):345\u201351.","journal-title":"Cancer"},{"issue":"11","key":"650_CR50","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1016\/j.leukres.2008.12.020","volume":"33","author":"A Vega-Ruiz","year":"2009","unstructured":"Vega-Ruiz A, Cortes JE, Sever M, Manshouri T, Quintas-Cardama A, Luthra R, et al. Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis. Leuk Res. 2009;33(11):1481\u20134.","journal-title":"Leuk Res"},{"key":"650_CR51","doi-asserted-by":"crossref","unstructured":"\u2022 Kasamon YL, Ko CW, Subramaniam S, Ma L, Yang Y, Nie L, et al. FDA approval summary: midostaurin for the treatment of advanced systemic mastocytosis. Oncologist. 2018;23(12):1511\u20139. Comprehensive review of the FDA approval of midostaurin, including review of trial endpoints.","DOI":"10.1634\/theoncologist.2018-0222"},{"issue":"2","key":"650_CR52","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1182\/blood-2004-12-4617","volume":"106","author":"JD Growney","year":"2005","unstructured":"Growney JD, Clark JJ, Adelsperger J, Stone R, Fabbro D, Griffin JD, et al. Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412. Blood. 2005;106(2):721\u20134.","journal-title":"Blood"},{"issue":"2","key":"650_CR53","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1182\/blood-2005-07-3022","volume":"107","author":"KV Gleixner","year":"2006","unstructured":"Gleixner KV, Mayerhofer M, Aichberger KJ, Derdak S, Sonneck K, Bohm A, et al. PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects. Blood. 2006;107(2):752\u20139.","journal-title":"Blood"},{"key":"650_CR54","doi-asserted-by":"publisher","unstructured":"Evans EK, Gardino AK, Kim JL, Hodous BL, Shutes A, Davis A, Zhu XJ, Schmidt-Kittler O, Wilson D, Wilson K, DiPietro L, Zhang Y, Brooijmans N, LaBranche TP, Wozniak A, Gebreyohannes YK, Sch\u00f6ffski P, Heinrich MC, DeAngelo DJ, Miller S, Wolf B, Kohl N, Guzi T, Lydon N, Boral A, Lengauer C. A precision therapy against cancers driven by KIT\/PDGFRA mutations. Sci Transl Med. 2017;9(414):eaao1690. https:\/\/doi.org\/10.1126\/scitranslmed.aao1690. PMID: 29093181.","DOI":"10.1126\/scitranslmed.aao1690"},{"key":"650_CR55","doi-asserted-by":"publisher","unstructured":"Al-Share B, Alloghbi A, Al Hallak MN, Uddin H, Azmi A, Mohammad RM, Kim SH, Shields AF, Philip PA. Gastrointestinal stromal tumor: a review of current and emerging therapies. Cancer Metastasis Rev. 2021;40(2):625-641. https:\/\/doi.org\/10.1007\/s10555-021-09961-7. Epub 2021 Apr 19. PMID: 33876372.","DOI":"10.1007\/s10555-021-09961-7"},{"key":"650_CR56","doi-asserted-by":"publisher","unstructured":"Serrano C. New treatments in advanced gastrointestinal stromal tumor. Curr Opin Oncol. 2021;33(4):323-328. https:\/\/doi.org\/10.1097\/CCO.0000000000000745. PMID: 33867479.","DOI":"10.1097\/CCO.0000000000000745"},{"key":"650_CR57","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Heinrich MC, Jones RL, von Mehren M, Schoffski P, Serrano C, Kang YK, et al. Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial. Lancet Oncol. 2020;21(7):935\u201346. Practice-changing study of avapritinib in rare gastrointestinal tumor.","DOI":"10.1016\/S1470-2045(20)30269-2"},{"issue":"Supplement 1","key":"650_CR58","first-page":"2","volume":"130","author":"DJ DeAngelo","year":"2017","unstructured":"DeAngelo DJ, Quiery AT, Radia D, Drummond MW, Gotlib J, Robinson WA, et al. Clinical activity in a phase 1 study of Blu-285, a potent, highly-selective inhibitor of KIT D816V in advanced systemic mastocytosis (AdvSM). Blood. 2017;130(Supplement 1):2.","journal-title":"Blood"},{"issue":"22","key":"650_CR59","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1182\/blood.V128.22.477.477","volume":"128","author":"MW Drummond","year":"2016","unstructured":"Drummond MW, DeAngelo DJ, Deininger MW, Radia D, Quiery AT, Hexner EO, et al. Preliminary safety and clinical activity in a phase 1 study of Blu-285, a potent, highly-selective inhibitor of KIT D816V in advanced systemic mastocytosis (SM). Blood. 2016;128(22):477.","journal-title":"Blood"},{"issue":"S1","key":"650_CR60","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1097\/01.HS9.0000561600.89121.38","volume":"3","author":"D Radia","year":"2019","unstructured":"Radia D, Deininger MW, Gotlib J, Bose P, Drummond MW, Hexner EO, et al. S830 avapritinib, a potent and selective inhibitor of KIT D816V, induces complete and durable responses in patients (pts) with advanced systemic mastocytosis (ADVSM). HemaSphere. 2019;3(S1):368.","journal-title":"HemaSphere"},{"key":"650_CR61","doi-asserted-by":"publisher","unstructured":"Daniel J. DeAngelo, Andreas Reiter, Deepti Radia, Michael W. Deininger, Tracy I. George, Jens Panse, Alessandro M. Vannucchi, Madlen Jentzsch, Iv\u00e1n Alvarez-Twose, Andrzej Mital, Olivier Hermine, Ingunn Dybedal, Elizabeth O. Hexner, Lisa K, Hicks, Lambert Span, Ruben Mesa, Prithviraj Bose, Kristen M. Pettit, Mark L. Heaney, Stephen Oh, Jayita Sen, Hui-Min Lin, Brenton G. Mar and Jason Gotlib. PATHFINDER: Interim analysis of avapritinib (ava) in patients (pts) with advanced systemic mastocytosis (AdvSM). Cancer Res. 2021;81(13 Supplement):CT023; https:\/\/doi.org\/10.1158\/1538-7445.AM2021-CT023.","DOI":"10.1158\/1538-7445.AM2021-CT023"},{"issue":"Supplement 1","key":"650_CR62","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1182\/blood-2020-136632","volume":"136","author":"C Akin","year":"2020","unstructured":"Akin C, Elberink HO, Gotlib J, Sabato V, Hartmann K, Broesby-Olsen S, et al. Pioneer part 2: a randomized, double-blind, placebo-controlled, phase 2 study to evaluate safety and efficacy of avapritinib in indolent systemic mastocytosis. Blood. 2020;136(Supplement 1):41\u20132.","journal-title":"Blood"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-021-00650-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11899-021-00650-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-021-00650-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T12:59:52Z","timestamp":1699534792000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11899-021-00650-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,27]]},"references-count":62,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["650"],"URL":"https:\/\/doi.org\/10.1007\/s11899-021-00650-4","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,27]]},"assertion":[{"value":"15 June 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Samantha Below declares no potential conflicts of interest. Laura C. Michaelis reports research funding from Jazz Pharmaceuticals and personal fees for consulting and advisory work from Celgene, Incyte Pharmaceuticals, and Curio Science.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article contains no studies with human or animal subjects performed by either of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}